ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class of drugs that antagonize some specific cell receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopp

Trial Details

NCT ID
NCT04055649
Phase
PHASE2
Sponsor
Ira Winer
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Akt/ERK Inhibitor ONC201
  • Paclitaxel
  • Questionnaire Administration
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Flint, Michigan, United States|43.01253,-83.68746

Key Eligibility Criteria

  • Histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Progressed within 6 months of completing at least 1 cycle of last platinum containing regimen. Patients with refractory disease (progression during…
  • No more than 4 prior treatment regimens defined as investigational, chemotherapy, hormonal, biologic, or targeted therapy in the platinum resistant…
  • At least one measurable lesion according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →